Impax to release Emverm chewable tablets
HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for its supplemental new drug application for Emverm 100-mg chewable tablets, a medication for parasitic worms. Ampex said Friday that Emverm (mebendazole) is indicated for the treatment of pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), common roundworm (Ascaris lumbricoides), common hookworm (Ancylostoma duodenale)
